Results 31 to 40 of about 31,920 (182)
Guillain–Barré Syndrome Associated with COVID-19 in a Japanese Male
Case Reports in Neurological Medicine, 2022 April 2021 saw a widespread outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Osaka, Japan. We encountered the case of a 52-year-old man who had Guillain–Barré syndrome associated with coronavirus disease 2019 (COVID-19).
Yoshiki Esa +7 more
doaj +1 more source
The Open General & Internal Medicine Journal, 2007 Guillain-Barre syndrome (GBS) is caused by an inflammatory polyradiculoneuropathy, which most commonly results from acute demyelination produced by a CD4 T-cell mediated response against myelin proteins. Axonal forms have also been recognized. Molecular mimicry between components of the bacterial wall of Campylobacter jejuni and gangliocytes in the ...
openaire +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar +6 more
wiley +1 more source
Guillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report
Journal of Nobel Medical College, 2021 Guillain-Barre Syndrome has been reported as a rare side effect in the recipients of Johnson & Johnson®'s Janssen Ad26.COV2.S COVID-19 vaccine. We report a case of Guillain-Barre Syndrome in a 50 years old female following the administration of the ...
Sushmita Khanal, Sunil Babu Khanal
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow +14 more
wiley +1 more source
Head &Neck, EarlyView.ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
Guillain-Barre Syndrome, Neuroborreliosis, or Both [PDF]
Cureus, 2020 Guillain-Barre syndrome (GBS) is an acute paralytic neuropathy. Limited reports of GBS caused by tick-borne pathogens exist. Lyme disease is a tick-borne infectious disease that is commonly caused by Borrelia burgdorferi. The nervous system may be involved and is called neuroborreliosis. In this case, we report a 30-year-old female who presented to the
Owens, Joey +2 more
openaire +2 more sources
A rare form of Guillain-Barré syndrome: pharyngeal-cervical-brachial variant
The Turkish Journal of Pediatrics, 2008 Guillain-Barré syndrome is clinically characterized by acute onset of generalized, symmetrical, and ascending muscle weakness and areflexia from peripheral nerve involvement. In Guillain-Barré syndrome variants, however, some patients have unusual
M Ozlem Hergüner +3 more
doaj
Case Reports in Neurological Medicine, 2013 Guillain-Barré syndrome is an immune-mediated polyneuropathy that frequently presents with progressive muscle weakness. Hyponatremia has recently been described as a feature of this condition, generally appearing over the course of the illness and ...
Benjamin Kloesel, LaTonya J. Hickson
doaj +1 more source
Movement Disorders, EarlyView.Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota +14 more
wiley +1 more source